Влияние стартовой дозы регорафениба на общую выживаемость пациентов с метастатическим раком толстой кишки: систематический обзор и метаанализ
- Авторы: Федянин М.Ю.1, Полянская Е.М.1, Трякин А.А.1, Покатаев И.А.1, Тюляндин С.А.1
-
Учреждения:
- ФГБУ «НМИЦ онкологии им. Н.Н. Блохина»
- Выпуск: Том 21, № 3 (2019)
- Страницы: 10-15
- Раздел: Статьи
- URL: https://journals.rcsi.science/1815-1434/article/view/33505
- DOI: https://doi.org/10.26442/18151434.2019.3.190651
- ID: 33505
Цитировать
Полный текст
Аннотация
Ключевые слова
Полный текст
Открыть статью на сайте журналаОб авторах
Михаил Юрьевич Федянин
ФГБУ «НМИЦ онкологии им. Н.Н. Блохина»
Email: fedianinmu@mail.ru
д-р мед. наук, ст. науч. сотр. отд-ния клин. фармакологии и химиотерапии Moscow, Russia
Елизавета Максимовна Полянская
ФГБУ «НМИЦ онкологии им. Н.Н. Блохина»
Email: lazimira@mail.ru
аспирант отд-ния клин. фармакологии и химиотерапии Moscow, Russia
Алексей Александрович Трякин
ФГБУ «НМИЦ онкологии им. Н.Н. Блохина»
Email: atryakin@gmail.com
д-р мед. наук, ст. науч. сотр. отд-ния клин. фармакологии и химиотерапии Moscow, Russia
Илья Анатольевич Покатаев
ФГБУ «НМИЦ онкологии им. Н.Н. Блохина»
Email: pokia@mail.ru
канд. мед. наук, ст. науч. сотр. отд-ния клин. фармакологии и химиотерапии Moscow, Russia
Сергей Алексеевич Тюляндин
ФГБУ «НМИЦ онкологии им. Н.Н. Блохина»
Email: stjulandin@gmail.com
д-р мед. наук, проф., зав. отд-нием клин. фармакологии и химиотерапии Moscow, Russia
Список литературы
- Li J, Qin S, Xu R et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2015; 16 (6): 619-29.
- Grothey A, Van Cutsem E, Sobrero Arto et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381: 303-12.
- Van Cutsem E, Martinelli E, Cascinu S et al. Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study. Oncologist 2019; 24 (2): 185-92.
- Schulz H, Janssen J, Strauss U.P et al. Clinical efficacy and safety of regorafenib (REG) in the treatment of metastatic colorectal cancer (mCRC) in daily practice in Germany: Final results of the prospective multicentre non-interventional RECORA study. J Clin Oncol 2018; 36 (Suppl. 4): 748.
- Kopeckova K, Chloupkova R, Melichar B et al. Regorafenib for metastatic colorectal carcinoma: a registry-based analysis. ESMO 2018. Abstract 468P.
- Del Prete S, Cennamo G, Leo L et al. Adherence and safety of regorafenib for patients with metastatic colorectal cancer: observational real-life study. Future Oncol 2017; 13 (5): 415-23.
- Aljubran A, Elshenawy M.A, Kandil M et al. Efficacy of Regorafenib in Metastatic Colorectal Cancer: A Multi-institutional Retrospective Study. Clinical Medicine Insights: Oncology 2019; 13: 1-6.
- Yamaguchi K, Komatsu Y, Satoh T et al. Large-Scale, prospective observational study of regorafenib in Japanese patients with metastatic colorectal cancer in a real-world clinical setting. Oncologist 2019. pii: theoncologist.2018-0377. doi: 10.1634/theoncologist.2018-0377.
- Tougeron D, de la Fouchardière C, Etienne P.L et al. REBECCA: A large cohort study of Regorafenib (REG) in the real-life setting in patients (pts) previously treated for metastatic colorectal cancer (mCRC). Ann Oncol 2014; 25 (Suppl. 4): iv167-iv209.
- Wilhelm S.M, Carter C, Tang L et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099-109.
- Escudier B, Szczylik C, Hutson T.E et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27: 1280-9.
- Mross K, Frost A, Steinbild S et al. A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res 2012; 18 (9): 2658-67.
- Gotfrit J, Vickers M, Sud S et al. Real-life treatment of metastatic colorectal cancer with regorafenib: a single-centre review. Curr Oncol 2017; 24 (4): 234-9.
- Adenis A, de la Fouchardiere C, Paule B et al. Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program. BMC Cancer 2016; 16: 412.
- Bekaii-Saab T.S, Ou F.S, Ahn D.H et al. Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study. Lancet Oncol 2019
- Argiles G, Mulet Margalef N, Valladares-Ayerbes M et al. Results of REARRANGE trial: A randomized phase 2 study comparing different dosing approaches for regorafenib (REG) during the first cycle of treatment in patients (pts) with metastatic colorectal cancer (mCRC). Ann Oncol 2019; 30 (Issue Suppl. 4): mdz154.025
- Angeles A, Hung W, Cheung W.Y. Eligibility of real-world patients with chemo-refractory, K-RAS wild-type, metastatic colorectal cancer for palliative intent regorafenib monotherapy. Med Oncol 2018; 35: 114.
- Kies M, Blumenschein G, Christensen O et al. Phase I study of regorafenib (BAY 73-4506), an inhibitor of oncogenic and angiogenic kinases, administered continuously in patients with advanced refractory non-small cell lung cancer. J Clin Oncol 2010; 28: abstr. #7585.
- Finn R.S, Blumenschein G, Tolcher A et al. Continuous-dose regorafenib (REG) in hepatocellular carcinoma (HCC): phase I safety and pharmacokinetic (PK) study. J Clin Oncol 2013; 31 (Suppl. 4):abstract 300.
- Kudo T, Kato Ti, Kagawa Y et al. Phase II dose titration study of regorafenib for patients with unresectable metastatic colorectal cancer that progressed after standard chemotherapy. J Clin Oncol 2018; 36 (Suppl. 4S); abstr 821.
- Petrioli R, Chirra M, Messuti L et al. Efficacy and safety of regorafenib with 2/1 schedule for patients ≥75 years with metastatic colorectal cancer (mCRC) after failure of 2 lines of chemotherapy. Clin Colorect Cancer 2018; 17: 307-12.
- Mayer R.J, Van Cutsem E, Falcone A et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 2015; 372 (20): 1909-19.
- Taieb J, Falcone A, Lonardi S et al. Safety and Efficacy of Trifluridine/Tipiracil(FTD/TPI) in Metastatic Colorectal Cancer (mCRC) Patients According to Previous Treatment With Regorafenib in the International Phase 3b PRECONNECT Study. Ann Oncol 2018; 29 (Suppl. 8): viii150-viii204.